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INTRODUCTION
Currently, non-gynecologic cancer therapy in women
who generally accept combination of high-dose che-
motherapy has been widely used and this is able to
increase the survival rate especially in young cancer
survivor. The survival rate in acute lymphocytic leu-
kemia and breast cancer for a notable example has
also been increased up to 67% and 75%.1 However,
some chemotherapeutic agents especially the alkyla-
ting agents can significantly deplete the ovarian re-
serve. Thus result in a reduction in fertility and an
increased risk of ovarian failure.2,3 The risk of meno-
pause and infertility has been shown to be a major
concern for young premenopausal cancer patients (as
if may give) a significant impact on self-esteem, sex-
ual function, and quality of life.
Ovarian dysfunction due to chemotherapy is char-
acterized by irregular menstrual pattern and amenor-
rhea. The incidence of amenorrhea due to chemother-
apy range from 21% - 71% to a adolescent and 49%
- 100% in the elderly. Amenorrhea generally will oc-
cur within 6 - 16 months post-chemotherapy in wo-
men under 40 years old and 2 - 4 months in women
over 40 years old.4 However, menstrual pattern may
not be used as an indicator of ovarian reserve, because
follicular depletion may occur despite maintenance of
regular menstrual cycles.5 Therefore, more accurate
indicators are needed to predict ovarian reserve.
Abstract
Objective: To assess the effect of combined chemotherapy on
levels of Anti-Müllerian Hormone (AMH).
Method: This is a prospective cohort study on 12 non-gyne-
cologic cancer women aged 20 - 40 years who received combined
chemotherapy treatment. AMH levels and menstrual pattern before
and after three months of chemotherapy were examined. The rela-
tionships between age, chemotherapy regimens and the cumulative
doses on the change of AMH were also analyzed.
Result: The median age of subjects was 37 years (range 20 - 40
years). Pre chemotherapy AMH analysis revealed an inverse corre-
lation between age and AMH levels (r = -0.715; p = 0.009). AMH
levels after 3 months of combined chemotherapy drastically de-
clined to 84.6% (p = 0.002). Multivariate analysis indicated that age
and total cumulative dose were the main factors contributing to the
AMH levels reduction (r = -0.679; p = 0.002 and r = 0.405; p =
0.027). Ten of 12 subjects (83.3%) experienced amenorrhea after
3 months of chemotherapy and had lower level of pre and post-
chemotherapy AMH compared to those who still maintained normal
periods (p = 0.03 and 0.02).
Conclusion: AMH levels in non-gynecological cancer women
who received combined chemotherapy decreased dramatically after
3 months of chemotherapy. Main factors that contribute to this were
the cumulative dose and age. Most of these subjects experienced
amenorrhea after 3 months of chemotherapy.
[Indones J Obstet Gynecol 2010; 34-3: 119-24]
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Abstrak
Tujuan: Mengetahui pengaruh kemoterapi kombinasi terhadap
kadar Anti Müllerian Hormone (AMH).
Metode: Penelitian ini merupakan studi kohort prospektif pada
12 pasien kanker non ginekologi berusia 20 - 40 tahun yang men-
dapatkan kemoterapi kombinasi. Kadar AMH dan pola haid se-
belum dan setelah tiga bulan kemoterapi diperiksa. Hubungan an-
tara faktor usia, rejimen kemoterapi dan dosis kumulatif terhadap
perubahan kadar AMH juga dianalisis.
Hasil: Median usia subjek adalah 37 tahun (rentang 20 - 40 ta-
hun). Analisis AMH pra kemoterapi menunjukkan korelasi terbalik
antara usia dengan kadar AMH (r = -0,715; p = 0,009). Kadar
AMH setelah 3 bulan pemberian kemoterapi kombinasi menurun
drastis hingga 84,6% (p = 0,002). Dari analisis multivariat dida-
patkan bahwa faktor usia dan dosis total kumulatif kemoterapilah
yang berperan terhadap penurunan kadar AMH (r = -0,679; p =
0,002 dan r = 0,405; p = 0,027). Sebanyak 10 dari 12 subjek
(83,3%) mengalami amenore setelah 3 bulan pemberian kemoterapi
dan memiliki kadar AMH prakemoterapi maupun pascakemoterapi
yang lebih rendah dibandingkan kelompok yang tetap memiliki haid
yang normal (p = 0,03 dan 0,02).
Kesimpulan: Kadar AMH penderita kanker non ginekologi yang
mendapatkan kemoterapi kombinasi menurun drastis setelah 3 bu-
lan pemberian kemoterapi dan faktor-faktor yang berperan ter-
hadap penurunan tersebut adalah dosis kumulatif dan usia. Se-
bagian besar subjek mengalami amenore setelah 3 bulan pemberian
kemoterapi.
[Maj Obstet Ginekol Indones 2010; 34-3: 119-24]
Kata kunci: cadangan ovarium, kemoterapi, Anti Müllerian
Hormone (AMH), fungsi ovarium, gonadotoksik
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Recently, AMH seems to represent the most prom-
ising predictor of ovarian reserve as it is expressed
in the ovarian granulosa cell of primary, preantral and
small antral follicles that more closely reflects the pri-
mordial follicular pool than other hormones. Addi-
tionally, AMH does not vary (within menstrual cy-
cle).6-8
Study by Anderson (et al) indicated that AMH can
be used as an early indicator of ovarian reserve decline
after 3 months of chemotherapy in breast cancer patients
given alkylating agents. This early decline of AMH con-
centration preceded the changes of other indicators.9
Potential risks of fertility dysfunction attributed by
chemotherapy agents are important to inform to the
patients before starting chemotherapy procedures.
Therefore, accurate ovarian reserve marker is needed
in order to know properly their reproductive capacity
after treatment and it may also help in considering a
particular effort of fertility preservation strategies.
Chemotherapy effects on fertility function in child-
hood cancer survivor has been widely studied, with
the result of a significant decline in AMH levels dur-
ing adulthood compared with normal women of the
same age. But there are still few prospective studies
and no study in Indonesia aimed to assess the effects
of chemotherapy on fertility function of reproductive
age. Therefore, this study was conducted to assess
prospectively AMH changes due to chemotherapy ef-
fects in non gynecologic cancer patients of reproduc-
tive age.
METHOD
The Medical Ethics Review Committee of University
of Indonesia approved this study and informed con-
sent was obtained from all participants. Fifteen new
cancer patients attending haematology and oncology
outpatient clinic of Internal department in RSCM and
also in Dharmais hospital between August 2009 and
March 2010 with: (i) nongynecologic cancer receiving
more than 1 chemotherapy agent; and (ii) between 17
and 40 years of age were included in the present
study. Patients were excluded if they had a history of
gynecologic disease/cancer, history of radiotherapy
and chemotherapy treatment, were currently pregnant,
and smoked.
The patients were evaluated at two study time
points: prechemotherapy (1 week before initiation of
chemotherapy) and 3 months after starting chemothe-
rapy (30 days after the first chemotherapy). At each
visit, serum AMH level (5 ml) was collected and men-
strual status was assessed. Serum samples for AMH
obtained and processed within 2 hours after with-
drawal. The samples was then freezed in –20°C until
assayed. AMH was measured using ELISA (Beckman
Coulter, Inc) with sensitivity 0.08 ng/ml. Serum analy-
sis were performed at MAKMAL laboratory Univer-
sity of Indonesia.
Significant differences between values of AMH
levels in each visits were calculated by using paired
t-test or the non-parametric Wilcoxon test. This main
statistic analysis procedure was run on SPSS version
16. A p-value < 0.05 indicates statistical significance.
RESULT
Within the research periods, 15 patients with median
age 37 years (range 20 - 40 years) were recruited to
the study. However, 3 of them dropped out. Two of
them were died from their disease and one patient
was lost to follow up. Finally, 12 women were eligi-
ble for analysis. The patients characteristics are sum-
marized in Table 1. Analysis of pretreatment hormone
showed significant negative correlations between age
and serum AMH (r = -0.715; p = 0.009) (Fig. 1). The
patients were then divided into 3 subgroups according
to their treatments and the type of cancer: breast can-
cer (group FAC, n = 6), NHL (group CHOP; n = 4),
and CLL (group COP; n = 2). Chemotherapy regi-
mens administered in 3 - 4 cycles with mean of total
cumulative doses were 4484.8 (SD 796.4) mg/m2.
Table 1. Patients characteristics.
Characteristics Subject (n=12)
Age (years) (median; range) 37 (20 - 40)
Marital states (%)
married 9 (75)
unmarried 3 (25)
BMI (kg/m2) (range ± SD) 22.84 ± 4.97
Parity (%)
Nulliparity 3 (25  )
Primiparity 1 ( 8.3)
Multiparity 8 (66.7)
Hormonal contraception
Yes 4 (33.3)
No 8 (66.7)
Cancer type and Chemotherapy regimens (%)
NHL (CHOP) 4 (33.3)
Breast cancer (FAC) 6 (50  )
CLL (COP) 2 (16.7)
Total dose of chemotherapy (mg/m2)
(range ± SD)
4484.8
± 796.4
Menstrual cycle prechemotherapy (%)
Normal 8 (66.7)
Oligomenorrhea 2 (16.7)
Amenorrhea 2 (16.7)
Abbreviation: CHOP, cyclophosphamide, doxorubicin, vincristine, pred-
nisolone; COP, cyclophosphamide, vincristine, prednisolone; FAC,
fluorouracil, adriamycin/doxorubicin, cyclophosphamide; CLL,
Chronic lymphositic leucemia; NHL, Non-Hodgkin lymphoma.
By Wilcoxon test, median AMH concentrations fell
significantly from 2.06 ng/ml (range 0.30 - 9.50) to
0.20 ng/ml (range 0.12 - 2.22) (p = 0.002) within 3
months after initiation of chemotherapy.
As mentioned earlier, there were 3 main treatment
groups: FAC, CHOP and COP. AMH level were com-
pared between treatment groups at the study time
points. The COP group was only represented by 2
patients, hence was not included in this analysis.
There were no significant differences in age in total
cumulative doses, pretreatment AMH (AMH1) and
AMH of 3 months after initial chemotherapy (AMH2)
between both FAC and CHOP groups. However, the
change of AMH level was significantly different be-
tween these two groups (Table 2).
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In Figure 2 it is shown that the correlation bet-
ween total cumulative doses and age with AMH was
decreasing. AMH decline was positively correlated
with total doses of chemotherapy (r = 0.610; p =
0.035) and negatively correlated with age (r = -0.817;
p = 0.001).
Factors affecting the drop in AMH level after 3
months of chemotherapy were analyzed by a multi-
variate linear regression analysis. On bivariate analy-
sis the chemotherapy regimens had significant rela-
tionship with AMH level change. However, age and
total cumulative doses of chemotherapy were the only
significant factors affecting AMH level decline during
3 months period of chemotherapy on multivariate
analysis (Table 3). The AMH level change estimated
using the regression equation: Y = 5.776 - 0.265 x
age + 0.001 x total cumulative dose.
Prior to chemotherapy, the majority of patients had
normal menstrual cycle (10 of 12 patients) with 2 of
them were amenorrheic. Three months after the initial
chemotherapy, 8 of 10 women from menstruating
group became amenorrheic and the two women re-
mained amenorrheic (Table 4).
Pre and post 3 months of chemotherapy, AMH le-
vel were found to be significantly lower among ame-
norrheic women compared to the menstruating groups
(2.47 ± 2.03 ng/ml vs 5.95 ± 5.03 ng/ml at baseline,
and 0.18 ± 0.02 ng/ml vs 1.91 ± 0.021 at 3 months;
p < 0.05 respectively).
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Figure 1. Correlation between age and prechemotherapy AMH
level.
Table 2. Patients characteristics based on chemotherapeutic regimens.
Regimens FAC (n=6) CHOP (n=4) p value
Age (year) 30.8  ± 7.9 36.5  ± 2.6 0.096
BMI (kg/m2) 24.4  ± 4.6 20.7  ± 6,6 0.636
Cumulative dose (mg/m2)   4982 ± 451.0   4189 ± 843.7 0.414
AMH1 (ng/ml)  4.48 ± 3.31  1.74 ± 0.40 0.073
AMH2 (ng/ml)  0.43 ± 0.58
(0.20)*
 0.17 ± 0.02
(0.16)*
 0.077**
ΔΑΜΗ (ΑΜΗ1 - AMH2) (ng/ml)  4.05 ± 2.93  1.57 ± 0.42 0.039
Data are mean ± SD for normal distribution and using unpaired t test;
* = median for abnormal distribution;
** = Mann Whitney U test.
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Figure 2a. Correlation between total cumulative doses of che-
motherapy and ΔAMH.
Age
20 25 30 35 40
0.00
2.00
4.00
8.00
6.00
Δ 
A
M
H
 (
n
g
/m
l)
Figure 2b. Correlation between age and ΔAMH.
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Table 4. Menstrual cycle characteristics.
Prechemotherapy
Three months after initial
chemotherapy
Menstruating
(n = 2)
Amenorrheic
(n = 10)
Menstruating (n = 10) 2 8
Amenorrheic (n = 2) 0 2
Age (years) 35.5 ± 6.3 33.8 ± 6.9
DISCUSSION
This study was conducted in women ages 17 - 40
years. This age selection aimed to assess the effect
of combined chemotherapy on AMH level especially
to the young cancer survivors (premenopausal age).
By knowing the baseline AMH level and its decline
after chemotherapy, counseling and treatment related
to the aspects of fertility preservation may be consid-
ered. Pretreatment fertility state in the current study
was shown indirectly from parity for married women,
menstrual cycles and no gynecological diseases. The
population of this study were nongynecologic cancer
patients. In order to minimize the selection bias of
fertility disorders due gynecological diseases or ma-
lignancies.
The finding in the current study that AMH concen-
trations decline with age is consistent with the study
of de Vat (et al), Van Rooj (et al) dan Anderson (et
al).9-11 This decline happened due to the primordial
follicles become atresia with advancing age. The ap-
proximate time of its decline is when women reach
37 years old. By that time, women may have been
menopause around 12 - 14 years later.11
Unlike previous studies which investigate chemo-
therapy effect on ovarian reserve by evaluating some
biochemical markers such as FSH, estradiol, inhibin
B, AMH and biophysical markers such as basal antral
follicles, this study specifically assess the gonadotoxic
effects of chemotherapy only by performing the AMH
level measurement. AMH is considered a direct mar-
ker of ovarian reserve, as it is produced by FSH-sen-
sitive early antral follicles. The decline of AMH level
was detected earlier than elevation of FSH level. It
has been confirmed by several observational studies
on the effects of chemotherapy, including breast can-
cer treatment protocols using intravenous cyclophos-
pamide.7,9
The primary analysis of AMH level changes in this
study were confined to the first 3 months, because
according to study by Anderson (et al) marked fall
of AMH level was indicated within 3 months of che-
motherapy.9 In the present study, AMH concentra-
tions fell dramatically by approximately 84.6% within
3 months of treatment. The dramatic falls in AMH
concentrations during combined chemotherapy using
alkylating agents may reflect severe gonadal toxicity
with primordial and preantral follicles as the primary
site of toxicity. The other hypothesis developed about
mechanism of ovarian reserve depletion by chemothe-
rapy is that it may affect not only on the resting pri-
mordial follicles directly but also indirectly by an in-
creased recruitment of primordial follicles. AMH is
known to inhibit recruitment of primordial follicles
into the pool of growing follicles. Therefore, the ab-
sence of AMH with elevated FSH level results in an
increased rate of recruitment of primordial follicles
which subsequently causes earlier exhaustion of the
primordial follicle pool and hence results in a more
rapid decline of AMH concentrations.12
Multiagents chemotherapy pose a greater risk on
ovarian function than the single agents chemotherapy.
All subjects in this study were treated with a 3-months
(3 - 4 cycles) multiagents chemotherapy that included
alkylating agents. As treatment was based on disease
staging and pathological grading, patients were not
randomized between treatments. The results of this
study indicate that ovarian reserve in CHOP group
seemed to be less damaged than in FAC group. This
is shown as FAC group had significantly larger ab-
solute changes of AMH (ΔAMH) concentrations (p =
0.039). Although there was significant difference of
the absolute value of ΔAMH concentrations between
the two groups, AMH decline was relatively similar
between FAC and CHOP groups (90.4% vs 90.2%).
It occured as these groups had no significant differ-
ence in total cumulative doses and each group con-
sisted of almost similar regimens of chemotherapy.
High total cumulative dose of chemotherapy has
been correlated with the premature ovarian failure in-
cidence characterized by amenorrheic condition ≥ 4
months and high FSH level (≥ 40 mIU/ml) occurred
at age less than 40 years.3,13 To date, there were no
studies that investigating the correlation between to-
tal cumulative doses with ovarian reserve especially
AMH concentrations. The majority of previous stu-
dies were limited to the investigation of correlation
Table 3. Multivariate analysis.
Variable B SE r p
Level 1 Coefficient  5.661 3.942
Chemotherapy
regimens  0.041 0.512  0.015 0.938
Age - 0.267 0.067 - 0.684 0.004
Total cumulative dose  0.001 0.001  0.411 0.052
Level 2 Coefficient  5.766 3.505 0.134
Age - 0.265 0.060 - 0.679 0.002
Total cumulative dose  0.001 0.000  0.405 0.027
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between cumulative doses of alkylating agents (as a
single or multiagents) with premature ovarian failure
incidence. The current study demonstrated that there
were significant positive correlation between total cu-
mulative doses of chemotherapy regimens with AMH
concentrations change (r = 0.610; p = 0.035).
The risk of ovarian failure in patients who receive
chemotherapy is closely related to the age, regimens
and higher cumulative doses. The present study found
that the main factors correlated to AMH decline dur-
ing 3 months of chemotherapy based on multivariate
analysis were age and total cumulative doses. While
chemotherapy regimens did not play a role in AMH
decline. This may be explained by quite similar type
of regimens and total cumulative doses between treat-
ment groups. This study also demonstrated more pro-
nounced changes in AMH among younger women.
This result was consistent with the result of study by
Anders (et al) (2008) that showed more pronounced
AMH concentrations changes found in breast cancer pa-
tients aged < 35 years (p = 0.003).14 There is plausible
explanation for this finding. In the cylic recruitment,
there are more cohort preaantral follicles in younger
age than the older women. This results in more affected
follicles due to chemotherapy which characterized by
more pronounced AMH decline in younger patients.
Normal menstrual cycle after chemotherapy does
not always indicate that there is no damage to the
ovaries because it is not an "all or nothing" phenome-
non. Primordial follicles depletion can occur partially
and hence the patients who still can ovulated after
chemotherapy administration remain at risk for pre-
mature menopause several years thereafter.15 The de-
gree of ovarian damage will determine whether ame-
norrhea will be permanent or temporary. If there are
minimum amount of oocytes, remains menstrual cycle
will have been irregular and the symptoms may de-
velop. On the contrary, if there are no remain oocytes,
the menstrual periods will stop.
In the present study, 10 of 12 (83.3%) patients be-
came amenorrheic after 3 months of treatment. This
result compares to a 55% rate of amenorrhea among
the breast cancer patients receiving combined chemo-
therapy reported by Anderson (et al) (2006).9
The AMH baseline in the current study is a useful
predictive marker for subsequent menstrual status af-
ter chemotherapy. Amenorrheic patients had lower
baseline AMH levels compared with menstruating pa-
tients (2.47 ± 2.03 ng/ml vs 5.95 ± 5.03 ng/ml, p =
0.03). This result contrasts to the study of Bo Yu (et
al) (2010) which demonstrated no significant different
in AMH baseline between amenorrheic patients and
menstruating patients.16 However, our study is sup-
ported by 2 previous studies on women with breast
cancer. Study by Anderson (et al) (2008) illustrated
that among 40 premenopausal patients treated with some
chemotherapy regimens; prechemotherapy AMH levels
were found to be lower among women who became
amenorrheic at 6 months after chemotherapy compared
to those who resumed menses (0.58 ng/ml vs 1.9 ng/ml;
p = 0.0007). In the study by Anderson (et al), among
women with chemotherapy related amenorrhea, pre-
chemotherapy median AMH levels were lower than
those who resumed menses (0.16 ng/ml vs 1.09
ng/ml; p = 0.02).9,14
Our study has some limitations, including a small
sample size and only 3 months of follow up. Due to
the short period of follow-up, the menstrual status was
only based on the presence or absence of menstruation
during this period. We realized that women may re-
sume menses despite low AMH levels after experi-
encing amenorrhea due to chemotherapy treatment as
demonstrated by Rosendahl (et al).17 Thus, in this
study, the longer period menstrual status was not able
to establish.
CONCLUSION
These data confirm gonadotoxic effect of combined
chemotherapy by significant decreased level of AMH
for 3 months since initial treatment. High total cumu-
lative doses and age were the main factors affecting
AMH changes. This study also demonstrated the high
incidence of amenorrhea during treatment and pre-
chemotherapy AMH level were found to be lower in
patients who experienced amenorrhea that menstruat-
ing patients.
Further larger and longer period studies were re-
quired to evaluate the reversibility of ovarian function
by evaluating AMH and menstrual pattern changes af-
ter chemotherapy has been completed. It is also nec-
essary to compare the type of chemotherapy regimens
(alkylating and non alkylating agents) effects to AMH
concentration.
REFERENCES
1. Meirow D. Reproduction post-chemotherapy in young can-
cer patients. Mol Cell Endocrinol 2000; 169: 123-31
2. Presti AL, Ruvolo G, Grancitano RA. Ovarian function fol-
lowing radiation and chemotherapy for cancer. Eur J Obstet
Gynecol Reprod Biol 2004; 113: 33-40
3. Anasti JN. Premature ovarian failure: an update. Fertil and
Steril 1998; 70: 1-13
4. Bines J, Oleske DM, Cobleigh MA. Ovarian function in
premenopausal women treated with adjuvant chemotherapy
for breast cancer. J Clin Oncol 1996; 14: 1718-29
5. Larsen EC, Muller J, Schmiegelow K. Diminished ovarian
reserve in female childhood cancer survivors with reguler
menstrual cycles and basal FSH < 10 IU/l. Hum Reprod
2003; 18(2): 417-22
6. Robert D, Marry M, Laven J. Anti-Müllerian hormone is
a sensitive serum marker for gonadal dysfunction in women
treated for Hodgkin’s lymphoma during childhood. J Clin
Endocrinol Metab 2007; 92: 3869-74
7. Singh KL, Davies M, Chatterjee R. Fertility in female can-
cer survivors: patophysiology, preservation and the role of
ovarian reserve testing. Hum Reprod Update 2005; 11(1):
69-89
8. Broekmans FJ, Visser JA, Laven JS. Anti-Müllerian hor-
mone and ovarian dysfunction. Trends in Endocrinol Metab
2008; 19(9): 340-7
9. Anderson RA, Themmen APN, Qahtani. The effects of che-
motherapy and long-term gonadotrophin suppression on the
ovarian reserve in premenopausal women with breast can-
cer. Hum Reprod 2006; 21(10): 2583-92
10. de Vat A, Laven JS, de Jong FH, Themmen AP, Fauser
BC. Antimüllerian hormone serum levels: a putative marker
for ovarian aging. Fertil Steril 2002; 77: 357-62
11. Van RoojIA, Broekmans FJ. Serum antimüllerian hormone
levels best reflect the reproductive decline with age in nor-
mal women with proven fertility: a longitudinal study. Fer-
til Steril 2005; 83: 979-87
Vol 34, No 3 |
July 2010 Gonadotoxic effect of combined chemotherapy on AMH  123
|
12. Durlinger. Anti-Müllerian hormone inhibits initiation of
primordial follicle growth in the mouse ovary. Endocrino-
logy 2002; 143: 1076-84
13. Kwon JS. Preserving reproductive function in women with
cancer. Sexuality, Reproduction & Menopause 2004; 2(4):
222-9
14. Anders C, Marcom K, Peterson B. A pilot study of predic-
tive markers of chemotherapy-related amenorrhea among
premenopausal women with early stage breast cancer. Can-
cer Invest 2008; 26: 286-95
15. Rose DP, Davis TE. Ovarian function in patients receiving
adjuvant chemotherapy for breast cancer. Lancet 1997; 1:
1174-6
16. Bo Yu, Douglas N, Ferin MJ. Changes in markers of ova-
rian reserve and endocrine factors in young women with
breast cancer undergoing adjuvant chemotherapy. Cancer
2010; 116: 2099-105
17. Rosendahl M, Andersen CY. Dynamics and mechanisms
of chemotherapy-induced ovarian follicular depletion in
women of fertile age. Fertil Steril 2010; 94: 156-66
| Indones J
124  Jasirwan and Sumapraja Obstet Gynecol
|
